Get started
Author

Eric R. Lutz

Targeting neoantigens to augment antitumour immunity
2017 · Mark Yarchoan, Burles A. Johnson, et al. · Nature reviews. Cancer · 994
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes –Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
2015 · Dung T. Le, Andrea Wang-Gillam, et al. · Journal of Clinical Oncology · 609
Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis
2017 · Takahiro Tsujikawa, Sushil Kumar, et al. · Cell Reports · 568
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
2013 · Dung T. Le, Eric Lutz, et al. · Journal of Immunotherapy · 564
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
2014 · Eric R. Lutz, Annie A. Wu, et al. · Cancer Immunology Research · 550
PDF
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells
2007 · Paul E. Zarek, Ching-Tai Huang, et al. · Blood · 515
PDF
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
2014 · Kevin C. Soares, Agnieszka A. Rucki, et al. · Journal of Immunotherapy · 399
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
2011 · Dung T. Le, Dirk G. Brockstedt, et al. · Clinical Cancer Research · 369
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
2004 · Amy Morck Thomas, Lynn M. Santarsiero, et al. · The Journal of Experimental Medicine · 347
PDF
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
2008 · Dan Laheru, Eric Lutz, et al. · Clinical Cancer Research · 346
PDF
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma
2018 · Alexander C. Hopkins, Mark Yarchoan, et al. · JCI Insight · 232
PDF
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer
2018 · Heather L. Kinkead, Alexander Hopkins, et al. · JCI Insight · 167
PDF
Erratum: Targeting neoantigens to augment antitumour immunity
2017 · Mark Yarchoan, Burles A. Johnson, et al. · Nature reviews. Cancer · 161
PDF
OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen
2006 · Satoshi Murata, Brian H Ladle, et al. · The Journal of Immunology · 106
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/ neu -Transgenic Mice
2003 · Matthew E Wolpoe, Eric R Lutz, et al. · The Journal of Immunology · 104
PDF
Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy
2014 · Eric R Lutz, Heather Kinkead, et al. · OncoImmunology · 40
PDF
A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas
2007 · D. Laheru, C. Yeo, et al. · Journal of Clinical Oncology · 30
Cancer Immunoprevention—The Next Frontier
2014 · Marie-Anne D. Smit, Elizabeth M. Jaffee, et al. · Cancer Prevention Research · 22
Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
2016 · Dung T. Le, Todd S. Crocenzi, et al. · Journal of Clinical Oncology · 13
Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival.
2015 · Chan Whiting, Eric Lutz, et al. · Journal of Clinical Oncology · 13
Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma
2024 · Colin S. Hill, Rose Parkinson, et al. · International Journal of Radiation Oncology*Biology*Physics · 10
Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)
2015 · Dung T Le, Todd S Crocenzi, et al. · Journal for ImmunoTherapy of Cancer · 10
PDF
Tumor Immunology: Basic and Clinical Advances
2011 · Pamela L. Beatty, Sandra Cascio, et al. · Cancer Research · 10
Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.
2019 · Adrian Gerard Murphy, Rosalind Walker, et al. · Journal of Clinical Oncology · 9
Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
2015 · Dung T. Le, Todd S. Crocenzi, et al. · Journal of Clinical Oncology · 9
Works count: 50
Citation count: 6,240
H-index: 18
I10-index: 22
Year
Topic
Type